PHARMACEUTICALS & MEDICAL DEVICES BUREAU OF INDIA (PMBI)

B-500, Tower B, 5th Floor, World Trade Center, Nauroji Nagar, New Delhi -110029

Minutes of Pre-bid Meeting dated 11/11/2026

Section I: Top Sheet

File No:	PMBI/07/77/PROC/2026	**Date:**	31/10/2026
Description	e-Tender no. PMBI/DRUG/RC-240/2026 dated 31.10.2026 for the supply of 140 nos. of Drugs/ Medicines to Pharmaceuticals & Medical Devices Bureau of India (PMBI) for two years.	**Estimated Cost: -**	Rs. 340.79 Crores approx.
Tender Published In	CPP-portal & PMBI website	**Date of Publication**	03.11.2026
Bid Validity	150 days	**Bid Opening Date**	To be opened as per tender schedule.
Advertisement of the tender	The tender has been advertised through widely circulated News-papers viz. ***Andhra Jyoti, Amar Ujala*** *(Dehradun City & New Delhi)* ***Dainik Jagran*** *(Dehradun City & Delhi City)****, Danik Bhaskar*** *(Ludhiana)****, Dinakaran Chennai, Divya Himachal, Danik Jagran*** *(Kanpur City)****, Hindustan Times*** *(Chandigarh/ Punjab, Lucknow City, New Delhi)****, Loksatta*** *(Mumbai, Pune)****, Sanmarg*** *(Kolkata City)****, Summit Times*** *(Sikkim).*		

Section II:

PMBI officials attended the meeting:

Sr. No.	Name	Designation	Tender Committee (TC)
1	N.J. Sujatha	Deputy Chief Executive Officer	Chairperson/ Member
2	Ravikant Tiwari	General Manager (Finance & Accounts)	Member
3	Sanjay Kumar	External Expert	Member
4	Rinku Giri	Manager (Sales & Marketing)	Member
5	Prateek Mishra	Manager (Sales & Marketing and Procurement)	Member
6	Sanjay Lohani	Manager (Logistics & Supply chain)	Member
7	Jay Prakash Mishra	Deputy General Manager (Procurement)	Procurement Department Head
8	Rishabh Nagar	Deputy Manager (Procurement)	To present tender to Tender Committee

Section III: Deliberation on Salient Features of the Tender:

At the onset of the meeting, Chairman, Tender Committee welcomed the representatives of the prospective bidders and briefed on the changes made in the current tender compared to the previous one. The few changes of all new clauses was deliberated upon during the session, and the representatives were advised to read the tender document carefully— paying particular attention to the major revisions under Clauses 1(B)(c), 3.A.i, 3.A.(v), 16.B, 16.E, 17.A, 18.M, 19. (o), 20 (B) and 21(A) as well as Annexures II, XI, XII, XIII, XIV, XVII, XVIII and XXIII. Additionally, they were instructed to strictly adhere to the prescribed formats in the tender wherever applicable. Also, the Chairman TC, elaborated on the revised tender condition regarding submission of Certificate of Pharmaceutical Product (CoPP), issued by the concerned Licensing Authority, for each product awarded under the contract and clarified that the bidder shall submit the respective CoPP certificates along with the Agreement after issuance of Letter of Acceptance (LoA).

Also, the Committee clarified the provisions regarding Performance Security Deposit, including submission of an irrevocable Bank Guarantee (BG) towards Performance Security Deposit at the rate of 3% of the Purchase value within 10 days, with a minimum validity of 36 months from the PO date, and BG shall be submitted in the prescribed format as per **Annexure XXIII**, along with the Agreement, and shall be released

within 60 days after completion of all contractual obligations, including shelf-life obligations.

The Committee deliberated upon and clarified the delivery timelines, stipulating that the delivery period shall be **45 days against the first Purchase Order (PO)** and **30 days against subsequent POs** for all drugs, except injectables, infusions and vials (products not requiring sterility testing).

Finally, regarding the price bid quotation (i.e., rate per tablet/ capsule), the Committee directed that the bidders must quote rates strictly according to the unit sizes specified in Annexures- XII, XIII, and the Bill of Quantities (BOQ).

Section IV: Queries of the intending bidders discussed during the pre-bid meeting

Pre-bid meeting against the subject tender was scheduled on 11/11/2026 from 11:00 hours onwards. The meeting was scheduled to be convened in physical mode at Conference Hall, PMBI as well as in hybrid mode where the link to join the meeting through video conference mode was provided to the intending bidders based on their request as per tender provisions.

2. PMBI has received queries from manufacturers through email prior to the pre-bid meeting whereas the below mentioned representatives have attended the pre-bid meeting through Hybrid mode and through video conference mode.

i. Synokem Pharmaceuticals Ltd.
ii. Zenith Drugs Ltd.
iii. Torque Pharmaceuticals Pvt. Ltd.
iv. Wings biotech LLP
v. Elnova Pharma

3. During meeting, the representatives of respective manufacturers were informed by the Committee regarding the recently updated in the tender conditions against the each quoted drugs, As per the tender conditions, PMBI reserves the right to conduct inspections of both new participant and existing manufacturers to verify compliance with the prescribed quality standards and ensure the required quality of products supplied under PMBI.

4. Later, the prospective bidders were requested to offer their views/ suggestions/ queries one by one regarding the terms & conditions and other details of the e-tender document followed by the other detailed discussion on the submitted queries.

5. Regarding terms and conditions/ detailed or packaging specifications, the representatives have offered their views/ suggestions/ queries and the same is discussed hereunder in the table:

S. No.	Manufacturer Name (M/s)	Query/ Suggestions of the representatives	PMBI Clarification
1.	Synokem Pharmaceuticals Ltd.	Representative of the manufacturer has requested the following: i. To accept the DC-1515 & 2073 with shelf-life of 18 months. ii. The bidder requested an extension of at least 15 days to the last date of bid submission, citing the ongoing festive season and the time required to arrange and submit the requisite documents.	Tendered committee, has informed to representative of the firm to refer amendment (if any) in this regard.
2.	Pulse Pharmaceuticals Pvt. Ltd.	Representative of the manufacturer has requested the Following: i. To amend the Generic Name and detailed specification for Item Code DC-834, Vitamin D3 IP 400 IU per ml to Vitamin D3 IP 400 IU per 0.5ml. ii. To amend the Generic Name and detailed specification of DC-1707 from Capsules to Uncoated tablet. iii. To amend the detailed specification of DC-1708 from Film-coated tablet to Uncoated tablet iv. To exempt the required three-years	The Tender Committee has noted the query raised by the firm and requested to refer the amendment (if any) in this regard.

		Market Standing Certificate in case of DC-2312 & 2156 stating that the patent for these products is expired in March 2025, and therefore it is not feasible for manufacturers to obtain a three-year MSC.	
3	Zenith Drugs Pvt. Ltd.	Representative of the manufacturer has requested for relaxation in submission of EMD/ bid-security for MSE manufacturers.	Tendered committee, has informed to representative of the firm to refer amendment (if any) in this regard
4	Wing biotech LLP	Representative of the manufacturer has requested the following: a. To amend the Generic Name and detailed specification of DC-1755, from Paracetamol Suspension IP 120mg to Paracetamol Suspension IP 125mg. b. To amend the Generic Name and detailed specification of DC-2630, from Sildenafil Tablets IP 20mg to Sildenafil Tablets IP 25mg. c. To allow submission of Performance Bank Guarantee (PBG) in lieu of cash deduction against all issued Purchase orders.	Tendered committee, has informed to representative of the firm to refer amendment (if any) in this regard
5	Torque Pharmaceutical Ltd.	Representative of the manufacturer has requested to modify/ extend the days of Delivery schedule.	Tendered committee, has informed to representative of the firm to refer amendment (if any) in this regard

The chair concluded the meeting with vote of thanks.

Sd/-
Chief Executive Officer,
Pharmaceuticals & Medical Devices Bureau of India